Androgen Receptor Phase Separation Linked to Gastric Cancer
Researchers have identified a molecular mechanism that drives tumor growth and offers a new path for cancer treatment.
Updated on Sept. 23, 2026 in Cancer
Scientists have discovered that the androgen receptor undergoes liquid-liquid phase separation, creating condensates that fuel gastric cancer progression. This process enhances chromatin accessibility and activates oncogenic programs, providing a potential new target for therapeutic intervention.
Why it matters
Understanding this fundamental pathogenic mechanism reveals how cancer cells bypass normal growth controls to proliferate. Disrupting these specific molecular condensates may provide a new way to treat patients who face poor prognoses.
A cohort study of 1,740 patients confirms elevated androgen receptor expression correlates with adverse outcomes. Preclinical models show that deleting the androgen receptor intrinsically disordered region 2 significantly suppresses tumor growth.
The players
Enzalutamide
This is an androgen receptor inhibitor currently used in clinical oncology settings.
AU-15330
This experimental compound is designed to target chromatin remodeling processes.
The details
The androgen receptor forms biomolecular condensates that recruit SWI/SNF chromatin remodeling complexes to boost oncogenic transcription. Preclinical tests demonstrated that the drug enzalutamide inhibits these condensates, while dual treatment with enzalutamide and AU-15330 produces synergistic antitumor effects.
Timeline
The research findings were published on September 23, 2026.
Deeper Dive
This study advances the field by characterizing the specific role of androgen receptor condensates as a driver in gastric cancer pathogenesis. It demonstrates how protein phase separation mechanisms, an emerging area of research, can be pharmacologically manipulated to stop tumor growth.
This discovery identifies a new biological target that may lead to the development of more effective, personalized treatment strategies for gastric cancer. Patients should discuss emerging therapeutic options and clinical trial eligibility with their oncology teams.
The takeaway
Targeting protein condensates represents a sophisticated evolution in cancer therapy that moves beyond traditional inhibition. Future treatments may leverage these mechanisms to achieve more precise tumor suppression with potentially fewer side effects.
Further reading
For more information on current clinical research, visit the Cancer section.
More information
Read the complete Nature research article for more technical data.
Source note: This article includes information reported by Nature.
